5.8 Tumor Classification: Histopathology, Grade & Staging Systems

Benign vs. Malignant Neoplasms

A neoplasm is any new, abnormal growth of tissue. Distinguishing benign from malignant growth is the first step in classification:

Histologic Classification

Malignant tumors are classified by the tissue of origin, since this determines behavior, spread pattern, and treatment approach:

• Carcinoma — arises from epithelial tissue (skin, glandular linings); the most common category of solid tumors. Subtypes include adenocarcinoma (glandular epithelium, e.g., prostate, colon, lung adenocarcinoma) and squamous cell carcinoma (squamous epithelium, e.g., skin, cervix, head and neck, esophagus).
• Sarcoma — arises from mesenchymal (connective) tissue: muscle (rhabdomyosarcoma, leiomyosarcoma), bone (osteosarcoma), cartilage (chondrosarcoma), fat (liposarcoma), or fibrous tissue (fibrosarcoma).
• Lymphoma — arises from lymphoid tissue (Hodgkin and non-Hodgkin lymphoma).
• Leukemia — arises from blood-forming (hematopoietic) cells in the bone marrow.
• Blastoma — arises from immature, embryonic ("blast") precursor cells, typically in children (e.g., nephroblastoma/Wilms tumor, neuroblastoma, retinoblastoma).
• Germ cell tumors — arise from primordial reproductive cells (e.g., seminoma, teratoma).

Grading: How Abnormal Do the Cells Look?

Grade describes how closely tumor cells resemble their normal tissue of origin under the microscope — a measure of differentiation, not extent of spread. Grading is generally reported on a scale from well-differentiated (low grade) to poorly differentiated/undifferentiated (high grade):

Site-specific grading systems refine this general framework: the Gleason score/Grade Group for prostate cancer and the FIGO grade for endometrial cancer are both differentiation-based systems adapted to their organ's specific histologic patterns. Higher grade generally correlates with a worse prognosis independent of stage, which is why grade and stage are reported and considered separately.

Staging: How Far Has the Tumor Spread?

Stage describes the anatomic extent of disease — how large the primary tumor is and whether it has spread to nodes or distant sites — and is the single most important prognostic factor for most solid tumors.

The TNM System

The American Joint Committee on Cancer (AJCC) TNM system is the dominant staging framework for solid tumors:

• T (Tumor) — size and/or local extent of the primary tumor (T1–T4, increasing with size/invasion).
• N (Nodes) — regional lymph node involvement (N0 = no nodal spread; N1–N3 = increasing nodal burden/extent).
• M (Metastasis) — presence of distant metastasis (M0 = none; M1 = distant metastasis present).

T, N, and M categories are combined into an overall stage group (Stage I–IV), where Stage I is early, localized disease and Stage IV indicates distant metastatic spread. Stage grouping is what typically drives treatment intent (curative vs. palliative) and modality selection.

Ann Arbor Staging (Lymphoma)

Because lymphoma spreads through the lymphatic system rather than by direct local invasion, it uses a distinct system based on the number and location of involved lymph node regions rather than tumor size:

An A or B suffix indicates the absence (A) or presence (B) of systemic symptoms — fever, night sweats, or unexplained weight loss — which itself carries prognostic weight.

FIGO Staging (Gynecologic Cancers)

Cervical, endometrial, ovarian, and vulvar cancers use the FIGO (International Federation of Gynecology and Obstetrics) staging system, which parallels TNM concepts (local extent, nodal involvement, distant spread) but uses gynecology-specific anatomic landmarks (e.g., parametrial extension, vaginal wall involvement) rather than the generic TNM categories.

Tumor Markers and the Pathology Report

Tumor markers are biochemical substances (often measured in blood) that can support diagnosis, monitor treatment response, or detect recurrence — examples include PSA (prostate), CA-125 (ovarian), CEA (colorectal), and AFP/beta-hCG (germ cell tumors). Markers are adjuncts, not stand-alone diagnostic tools; a rising marker prompts further imaging or biopsy rather than an immediate treatment change on its own.

The pathology report is the definitive source for histologic type, grade, and (with imaging/surgical findings) stage, and the therapist should understand its major elements:

Grade and stage are reported and used independently because they measure different things — grade reflects biologic aggressiveness at the cellular level, while stage reflects how far disease has already spread; a low-grade tumor can still present at an advanced stage, and a high-grade tumor can be caught early.

Why This Matters for the Radiation Therapist

The therapist does not assign grade or stage, but daily practice depends on understanding them. Field size, dose, and fractionation are frequently stage-dependent (e.g., elective nodal coverage expands as N-stage increases), while treatment intent — curative versus palliative — is often set by whether M0 or M1 disease is documented in the chart. Recognizing histologic type on the chart (adenocarcinoma versus squamous cell carcinoma versus sarcoma, for example) also helps the therapist anticipate which normal-tissue tolerances and immobilization strategies the physician is likely to prioritize, since sarcoma compartment-based fields, gynecologic brachytherapy applicators, and head and neck nodal volumes all reflect the classification concepts covered in this section.